Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 716

1.

Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.

Zinzani PL, Rambaldi A, Gaidano G, Girmenia C, Marchetti M, Pane F, Tura S, Barosi G.

Leuk Res. 2019 Jun;81:88-94. doi: 10.1016/j.leukres.2019.04.016. Epub 2019 May 2. Review.

PMID:
31055248
2.

Response to "Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions" by Heidel et al.

Barosi G, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barbui T.

Leukemia. 2018 Dec;32(12):2727-2728. doi: 10.1038/s41375-018-0259-x. Epub 2018 Sep 28. No abstract available.

PMID:
30267006
3.

Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera.

Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barosi G.

Leukemia. 2018 Sep;32(9):2077-2081. doi: 10.1038/s41375-018-0199-5. Epub 2018 Jun 28. No abstract available.

PMID:
29955128
4.

Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.

Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S, Mecucci C; MORE Study Centres.

Eur J Haematol. 2018 Jul;101(1):78-85. doi: 10.1111/ejh.13067. Epub 2018 May 22.

PMID:
29569278
5.

Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.

Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S.

Leuk Res. 2017 Nov;62:108-115. doi: 10.1016/j.leukres.2017.10.001. Epub 2017 Oct 5. Review.

PMID:
29054020
6.

Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology.

Guglielmelli P, Pietra D, Pane F, Pancrazzi A, Cazzola M, Vannucchi AM, Tura S, Barosi G.

Leuk Res. 2017 Jul;58:63-72. doi: 10.1016/j.leukres.2017.04.006. Epub 2017 Apr 23. Review.

PMID:
28460339
7.

Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper.

Zinzani PL, Corradini P, Martelli M, Minotti G, Oliva S, Spina M, Barosi G, Tura S.

Eur J Haematol. 2016 Dec;97(6):554-561. doi: 10.1111/ejh.12768. Epub 2016 Jul 1.

PMID:
27124765
8.

Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.

Zinzani PL, Corradini P, Gianni AM, Federico M, Santoro A, Vitolo U, Barosi G, Tura S.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):507-13. doi: 10.1016/j.clml.2015.06.008. Epub 2015 Jun 19. Review.

PMID:
26195435
9.

Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.

Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaccaria A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Tura S, Vitolo U.

Leuk Lymphoma. 2015 Jun;56(6):1671-6. doi: 10.3109/10428194.2014.964702. Epub 2014 Nov 19.

PMID:
25241999
10.

Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma).

Tarella C, Arcaini L, Baldini L, Barosi G, Billio A, Marchetti M, Rambaldi A, Vitolo U, Zinzani PL, Tura S.

Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):75-85. doi: 10.1016/j.clml.2014.07.002. Epub 2014 Jul 15. Review.

PMID:
25108679
11.

Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.

Cuneo A, Marchetti M, Barosi G, Billio A, Brugiatelli M, Ciolli S, Laurenti L, Mauro FR, Molica S, Montillo M, Zinzani P, Tura S.

Leuk Res. 2014 Nov;38(11):1269-77. doi: 10.1016/j.leukres.2014.06.017. Epub 2014 Jul 7.

PMID:
25063524
12.

SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias.

Corradini P, Marchetti M, Barosi G, Billio A, Gallamini A, Pileri S, Pimpinelli N, Rossi G, Zinzani PL, Tura S.

Ann Oncol. 2014 Dec;25(12):2339-50. doi: 10.1093/annonc/mdu152. Epub 2014 Apr 9.

13.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID:
24580147
14.

Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.

Barosi G, Vannucchi AM, De Stefano V, Pane F, Passamonti F, Rambaldi A, Saglio G, Barbui T, Tura S.

Leuk Res. 2014 Feb;38(2):155-60. doi: 10.1016/j.leukres.2013.09.008. Epub 2013 Sep 19.

PMID:
24378116
15.

Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups.

Onida F, Barosi G, Leone G, Malcovati L, Morra E, Santini V, Specchia G, Tura S.

Haematologica. 2013 Sep;98(9):1344-52. doi: 10.3324/haematol.2013.084020. Review.

16.

Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making.

Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F, Tosi P, Zinzani P, Tura S.

Leukemia. 2013 Apr;27(5):997-9. doi: 10.1038/leu.2012.303. No abstract available.

PMID:
23653072
17.

SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.

Zinzani PL, Marchetti M, Billio A, Barosi G, Carella AM, Lazzarino M, Martelli M, Rambaldi A, Rigacci L, Tarella C, Vitolo U, Tura S; Expert Panel of the Italian Society of Hematology.

Am J Hematol. 2013 Mar;88(3):185-92. doi: 10.1002/ajh.23372. Epub 2013 Jan 22.

18.

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.

Barosi G, Merlini G, Billio A, Boccadoro M, Corradini P, Marchetti M, Massaia M, Tosi P, Palumbo A, Cavo M, Tura S.

Ann Hematol. 2012 Jun;91(6):875-88. doi: 10.1007/s00277-012-1445-y. Epub 2012 Apr 4. Review.

PMID:
22476884
19.

Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study.

Oliva EN, Piccin A, Mazzucconi MG, Morra E, Recine U, Pogliani EM, Pane F, Gobbi M, Gugliotta L, Krampera M, Cascavilla N, Cacciola R, Cacciola E, Fioritoni G, Fanin R, Liberati AM, Angelucci E, Tura S.

Ann Hematol. 2012 Apr;91(4):527-32. doi: 10.1007/s00277-011-1341-x. Epub 2011 Oct 1.

PMID:
21964878
20.

SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.

Mauro FR, Bandini G, Barosi G, Billio A, Brugiatelli M, Cuneo A, Lauria F, Liso V, Marchetti M, Meloni G, Montillo M, Zinzani P, Tura S; Italian Society of Hematology; SocietĂ  Italiana di Ematologia Sperimentale; Gruppo Italiano Trapianto di Midollo Osseo.

Leuk Res. 2012 Apr;36(4):459-66. doi: 10.1016/j.leukres.2011.08.013. Epub 2011 Sep 1.

PMID:
21885123
21.

Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.

Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, Corradini P, Pane F, Tura S.

Haematologica. 2011 Jul;96(7):937-42. doi: 10.3324/haematol.2011.041210. No abstract available.

22.

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S; Italian Society of Hematology.

Leuk Res. 2010 Dec;34(12):1576-88. doi: 10.1016/j.leukres.2010.01.018. Epub 2010 Feb 11.

PMID:
20149927
23.

Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.

Vitolo U, Barosi G, Fanti S, Gianni AM, Martelli M, Petrini M, Zinzani PL, Tura S.

Am J Hematol. 2010 Feb;85(2):147-55. doi: 10.1002/ajh.21602. No abstract available.

24.

Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.

Brusamolino E, Bacigalupo A, Barosi G, Biti G, Gobbi PG, Levis A, Marchetti M, Santoro A, Zinzani PL, Tura S.

Haematologica. 2009 Apr;94(4):550-65. doi: 10.3324/haematol.2008.002451. Epub 2009 Mar 10.

25.

Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.

Morra E, Barosi G, Bosi A, Ferrara F, Locatelli F, Marchetti M, Martinelli G, Mecucci C, Vignetti M, Tura S.

Haematologica. 2009 Jan;94(1):102-12. doi: 10.3324/haematol.13166. Epub 2008 Nov 10.

26.

Consensus conference on the management of tumor lysis syndrome.

Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, Morra E, Pession A, Rosti G, Santoro A, Zinzani PL, Tura S.

Haematologica. 2008 Dec;93(12):1877-85. doi: 10.3324/haematol.13290. Epub 2008 Oct 6.

27.

Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Zinzani PL, Martelli M, Poletti V, Vitolo U, Gobbi PG, Chisesi T, Barosi G, Ferreri AJ, Marchetti M, Pimpinelli N, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation.

Haematologica. 2008 Sep;93(9):1364-71. doi: 10.3324/haematol.12742. Epub 2008 Jul 4.

28.

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

Angelucci E, Barosi G, Camaschella C, Cappellini MD, Cazzola M, Galanello R, Marchetti M, Piga A, Tura S.

Haematologica. 2008 May;93(5):741-52. doi: 10.3324/haematol.12413. Epub 2008 Apr 15.

29.

Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation.

Tosi P, Terragna C, Testoni N, Zamagni E, Renzulli M, Tacchetti P, Montanari E, Perrone G, Ceccolini M, Brioli A, Pallotti MC, Tura S, Baccarani M, Cavo M.

Eur J Haematol. 2008 Jan;80(1):31-6. Epub 2007 Nov 23.

PMID:
18036184
30.

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.

Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S, Cangini D, Narni F, Carubelli A, Masini L, Catalano L, Fiacchini M, de Vivo A, Gozzetti A, Lazzaro A, Tura S, Baccarani M.

J Clin Oncol. 2007 Jun 10;25(17):2434-41. Epub 2007 May 7.

PMID:
17485707
31.

Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M, Mauro FR, Meloni G, Zinzani PL, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation.

Haematologica. 2006 Dec;91(12):1662-73.

32.

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.

Tosi P, Zamagni E, Cangini D, Tacchetti P, Di Raimondo F, Catalano L, D'Arco A, Ronconi S, Cellini C, Offidani M, Perrone G, Ceccolini M, Brioli A, Tura S, Baccarani M, Cavo M.

Blood. 2006 Dec 1;108(12):3951-2. No abstract available.

PMID:
17114572
33.

Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes.

Catani L, Fagioli ME, Tazzari PL, Ricci F, Curti A, Rovito M, Preda P, Chirumbolo G, Amabile M, Lemoli RM, Tura S, Conte R, Baccarani M, Vianelli N.

Exp Hematol. 2006 Jul;34(7):879-87.

PMID:
16797415
34.

Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases.

Lorenzini S, Andreone P, Gramenzi A, Morelli C, Zinzani PL, Grazi GL, Pileri S, Baccarani M, Tura S, Bernardi M.

Transplant Proc. 2006 Jun;38(5):1477-80.

PMID:
16797338
35.

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.

Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G, Ceccolini M, Boni P, Tura S, Baccarani M, Cavo M.

Eur J Haematol. 2006 May;76(5):399-404. Epub 2006 Feb 15.

PMID:
16480429
36.

Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, Tarella C, Vitolo U, Zinzani PL, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation.

Haematologica. 2006 Jan;91(1):96-103.

37.
38.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, de Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M; Bologna 2002 study.

Blood. 2005 Jul 1;106(1):35-9. Epub 2005 Mar 10.

PMID:
15761019
39.

Immune therapy of chronic myelogenous leukemia.

Gale RP, Horowitz MM, Talpaz M, Scheinberg DA, Molldrem J, Li Z, Baccarani M, Goldman JM, Tura S.

Leuk Res. 2005 May;29(5):583-6. No abstract available.

PMID:
15755511
40.

Stem cell plasticity: time for a reappraisal?

Lemoli RM, Bertolini F, Cancedda R, De Luca M, Del Santo A, Ferrari G, Ferrari S, Martino G, Mavilio F, Tura S.

Haematologica. 2005 Mar;90(3):360-81. Review.

41.

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.

Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M.

Eur J Haematol. 2005 Mar;74(3):212-6.

PMID:
15693790
42.

Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.

Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, Barbui T, Tura S, Baccaranion M; Gruppo Italiano per lo Studio delle Malattie Ematologiche dell'Adulto.

Haematologica. 2005 Jan;90(1):72-7.

43.

No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?

Visani G, Isidori A, Grafone T, Tosi P, Santini V, Malagola M, Martinelli G, Piccaluga PP, Gaziev D, Ottaviani E, Sparaventi G, Tura S.

Leuk Lymphoma. 2004 Jul;45(7):1361-4.

PMID:
15359633
44.

Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells.

Tenedini E, Fagioli ME, Vianelli N, Tazzari PL, Ricci F, Tagliafico E, Ricci P, Gugliotta L, Martinelli G, Tura S, Baccarani M, Ferrari S, Catani L.

Blood. 2004 Nov 15;104(10):3126-35. Epub 2004 Jul 22.

PMID:
15271793
45.

First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.

Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti G, Tura S, Baccarani M.

Haematologica. 2004 Jul;89(7):826-31.

46.

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.

Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S, Baccarani M, Cavo M.

Eur J Haematol. 2004 Aug;73(2):98-103.

PMID:
15245508
47.

Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.

Zinzani PL, Pulsoni A, Gentilini P, Visani G, Perrotti A, Molinari AL, Guardigni L, Tani M, VillivĂ  N, Stefoni V, Alinari L, Martelli M, Bonifazi F, Pileri S, Tura S, Baccarani M.

Leuk Lymphoma. 2004 Sep;45(9):1815-9.

PMID:
15223641
48.

Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).

Barosi G, Boccadoro M, Cavo M, Corradini P, Marchetti M, Massaia M, Merlini G, Tosi P, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation.

Haematologica. 2004 Jun;89(6):717-41. Review.

49.

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.

Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M.

J Clin Oncol. 2004 Jul 1;22(13):2654-61. Epub 2004 May 24.

PMID:
15159414
50.

High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience.

Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, De Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Guidice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Marchi E, Bassi S, Conte R, Pileri S, Tura S, Baccarani M.

Leuk Lymphoma. 2004 Feb;45(2):321-6.

PMID:
15101718

Supplemental Content

Support Center